Contrast Media and Nephropathy: Findings From Systematic Analysis and Food and Drug Administration Reports of Adverse Effects

Context:Recent studies suggest differences in the incidence of contrast-induced nephropathy (CIN) among contrast media (CM). Objective:To determine whether there are significant differences among low-osmolality CM (LOCM) in the incidence of contrast-induced nephropathy (CIN), we reviewed published studies of CIN in renally impaired patients and conducted statistical data mining using databases of adverse events maintained by the U.S. Food and Drug Administration (FDA). Data Sources:A systematic literature search was performed for prospective, controlled, English language studies published in peer-reviewed journals that reported CIN rates in renally impaired patients after a specific LOCM. Databases searched were EMBASE, MEDLINE, Biosis Previews, Derwent Drug File, Pascal, and SciScearch Cited Ref Sci. For the FDA analysis, we used the SRS and AERS databases. Data Selection:Twenty-two studies reporting data in 3112 patients with renal impairment met the inclusion criteria. Most studies reported on the use of a pharmacologic intervention to prevent CIN. From the FDA databases, we evaluated 18 adverse event terms associated with renal injury or dysfunction after CM use. Data Extraction:Data from 22 studies were entered into a database. A meta-regression analysis using a mixed effect model was performed. CM effect was adjusted by the following covariates: baseline patient characteristics (mean age, gender distribution) and risk factors (prevalence of diabetes mellitus, degree of renal impairment, CM volume), and the use of prophylactic drug treatments. Multiple disproportionality analyses (adjusted odds ratio, adjusted empirical Bayesian estimate, or Bayesian logistic regression) were performed on the FDA databases to estimate associations between 4 CM and 18 AE terms related to CIN. Data Synthesis:Systematic analysis of clinical trials suggest the highest incidence of CIN occurs in patients receiving iohexol and the lowest incidence in patients receiving iopamidol, even when corrected for other CIN risk factors. Statistical data mining of FDA data also showed the highest association of CIN for iohexol and the lowest for iopamidol. Conclusions:The risk of CIN was higher in patients receiving iohexol compared with patients receiving iopamidol. No significant differences were found comparing iohexol to other LOCMs, including iodixanol.

[1]  H. Thomsen,et al.  Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. , 2003, The British journal of radiology.

[2]  R E Vlietstra,et al.  A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. , 1991, Journal of the American College of Cardiology.

[3]  Sonia S Anand,et al.  Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. , 2002, Vascular medicine.

[4]  M. Leon,et al.  Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. , 1999, The American journal of cardiology.

[5]  Sven-Göran Fransson,et al.  Nephrotoxic effects in high-risk patients undergoing angiography. , 2003, The New England journal of medicine.

[6]  N. Chalmers,et al.  Comparison of iodixanol and iohexol in renal impairment. , 1999, The British journal of radiology.

[7]  S. Rezkalla,et al.  Contrast nephropathy. , 2003, Clinical medicine & research.

[8]  Samin K. Sharma,et al.  Effect of nonionic radiocontrast agents on the occurrence of contrast‐induced nephropathy in patients with mild‐moderate chronic renal insufficiency: Pooled analysis of the randomized trials , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[9]  K. Shyu,et al.  Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. , 2002, Journal of the American College of Cardiology.

[10]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[11]  Stephanie Chung,et al.  Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms , 2004, European Journal of Clinical Pharmacology.

[12]  A. Wragg,et al.  A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. , 2003, Journal of the American College of Cardiology.

[13]  Douglas Losordo,et al.  Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). , 2002, The American journal of cardiology.

[14]  G. Marenzi,et al.  The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. , 2003, The New England journal of medicine.

[15]  B. Barrett,et al.  Follow-up of patients with contrast-induced nephropathy. , 2006, Kidney international. Supplement.

[16]  R. Solomon.  The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. , 2005, Kidney international.

[17]  D. Hilleman,et al.  Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. , 2003, American heart journal.

[18]  Rawlins,et al.  Attitudinal survey of voluntary reporting of adverse drug reactions. , 1999, British journal of clinical pharmacology.

[19]  A. Colombo,et al.  N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. , 2004, Journal of the American College of Cardiology.

[20]  E. Halpern,et al.  Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. , 1995, Kidney international.

[21]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[22]  J. Sanderson,et al.  Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  S. Evans,et al.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.

[24]  P. McLaughlin,et al.  N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. , 2004, American heart journal.

[25]  W. F. Mason,et al.  A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography. , 1990, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[26]  M. Cova,et al.  Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial , 1998, European Radiology.

[27]  P. McCullough,et al.  Epidemiology of contrast-induced nephropathy. , 2003, Reviews in cardiovascular medicine.

[28]  A. Levin,et al.  A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. , 2004, American heart journal.

[29]  S. Fishbane,et al.  A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. , 2002, Kidney international.

[30]  Chi‐Hang Lee,et al.  Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. , 2003, JAMA.

[31]  E. Schwammenthal,et al.  Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. , 2004, European heart journal.

[32]  W. DuMouchel,et al.  Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post‐marketing setting , 2003, Pharmacoepidemiology and drug safety.

[33]  W. O’Neill,et al.  Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. , 1997, The American journal of medicine.

[34]  G. Dangas,et al.  The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. , 2000, Journal of the American College of Cardiology.

[35]  B Müller-Oerlinghausen,et al.  Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. , 2002, Journal of clinical epidemiology.

[36]  M. Seyfarth,et al.  Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. , 2003, The American journal of cardiology.

[37]  A. Colombo,et al.  Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. , 2004, European heart journal.

[38]  B. Villari,et al.  Acetylcysteine and contrast agent-associated nephrotoxicity. , 2002, Journal of the American College of Cardiology.

[39]  S. Sdringola,et al.  Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[40]  C. Dmuchowski,et al.  Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. , 1998, The American surgeon.

[41]  M. Bell,et al.  The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. , 2002, Journal of the American College of Cardiology.

[42]  B. Barrett,et al.  Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. , 1993, Radiology.

[43]  R. O’Neill,et al.  Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.

[44]  A. Lansner,et al.  Bayesian neural networks with confidence estimations applied to data mining , 2000 .